Compass Capital Corp /Ma/ /Adv Alnylam Pharmaceuticals, Inc. Transaction History
Compass Capital Corp /Ma/ /Adv
- $257 Billion
- Q4 2024
A detailed history of Compass Capital Corp /Ma/ /Adv transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Compass Capital Corp /Ma/ /Adv holds 800 shares of ALNY stock, worth $219,640. This represents 0.08% of its overall portfolio holdings.
Number of Shares
800Holding current value
$219,640% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
651Shares Held
109MCall Options Held
1.28MPut Options Held
1.23M-
Capital World Investors Los Angeles, CA16.5MShares$4.53 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.47 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.62 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.44 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.36 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...